Introduction:
The article discusses the need for standardized access portals in the cell and gene therapy (CGT) industry in order to address the growing demand for these therapies and ensure efficient coordination between providers and patients. Lack of standardization poses a threat to patient access and overall market development. The article proposes the creation of a standardized environment through collaboration and co-innovation among industry players.
- The FDA’s approval of a new gene editing treatment for sickle cell disease indicates the potential for a surge in CGT activity in the coming years.
- However, the lack of standardization in access portals for CGT treatments poses a threat to patient access and market development.
- A standardized user experience can be achieved through the creation of an integrated hub that allows providers and patients to easily access and manage multiple treatments from different manufacturers.
- The growth of the CGT market will require coordination, collaboration, and consensus among stakeholders across the value chain, including manufacturers, treatment facilities, suppliers, logistics providers, laboratories, and insurers.
- Standardization efforts should focus on creating a digital environment that is intuitive, secure, transparent, and compliant.
Conclusion:
The article emphasizes the need for standardized access portals in the CGT industry to ensure efficient coordination and patient access to treatments. Collaboration and co-innovation among industry players are necessary to create a standardized environment that benefits patients, providers, and the overall market. Back-end elements, such as connected business networks, trust among data sharers, widely accepted standards and policies, modern digital systems, and real-time communications channels, must also be in place to support a standardized user experience. Strengthening and streamlining back-end processes will contribute to establishing a sustainable business model in the CGT industry.
